Abstract: Enteroviruses and human parechoviruses usually cause mild, self-limiting illnesses in children but can occasionally cause severe disease. During 2010-2014, 104 children in the United Kingdom and the Republic of Ireland were admitted to a pediatric intensive care unit with severe enterovirus and human parechovirus infection; 40% had neurologic symptoms, 20% respiratory failure, 16% cardiac complications and 11% septic shock. Annual number of cases and incidence increased in the possibility of hospital-acquired infection; but they were found negative for C. indologenes upon culture.
C. indologenes was isolated for the first time from tracheal aspirate sample obtained from a patient with ventilator-associated pneumonia by Bonten et al. 5 Hsueh et al 6 found increasing incidence of healthcare-associated infection because of C. indologenes in patients with indwelling devices, and majority of the cases have been reported from Taiwan. 7 Very few cases have been reported in infants till date as compared with adults, which may be due to lower frequency of comorbidities in pediatric population. 8 We have summarized the published reported clinical cases in pediatric population by C. indologenes in the present study (Table 1) . 2, 4, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Almost all cases were associated with congenital malformations though none in our study had any congenital malformations. In present case report, C. indologenes was isolated from the tracheal aspirate of 2 neonates admitted in NICU. They received ventilation for approximately a week before isolation of C. indologenes. Blood and CSF samples collected on the day of admission in both the cases were sterile; however, subsequent culture of tracheal aspirate showed growth of C. indologenes. Since bacterial isolates from both the cases were obtained around the same time, attempts were made to identify the source of C. indologenes by environmental sampling, but we were unable to isolate C. indologenes from any inanimate environment source. A retrospective study done in 215 cases during 2004-2011 suggests C. indologenes as emergent pathogen, likely due to increased use of broad-spectrum antibiotics such as colistin and tigecycline for treating carbapenem-resistant pathogens. 7 Chryseobacterium species produce β-lactamases and are usually resistant to most β-lactam antibiotics including carbapenems and monobactams, though cases have been reported where cefepime, ceftriaxone and imipenem have shown in vitro activity against C. indologenes. [9] [10] [11] [12] [13] Chryseobacterium species are usually resistant to aminoglycosides, tetracyclines, chloramphenicol, erythromycin, clindamycin and teicoplanin. 1 Minimum inhibitory concentration breakpoints are not established by Clinical and Laboratory Standards Institute for Chryseobacterium species. 1 In present study, both isolates were resistant to all antibiotics including colistin, except trimethoprim/sulfamethoxazole.
Chryseobacterium species are resistant to most of antibiotics currently used empirically for the treatment of infections caused by Gram-negative rods, it is conceivable that it will survive in an environment with frequent exposure to these drugs. Increased use of broad-spectrum antibiotics, such as carbapenem and colistin, may further help in its survival, which may result in nosocomial infection by this bacterium. Timely identification of causative agent with appropriate antibiotic initiation saved lives of these 2 neonates. referenCes nterovirus (EV) and human parechovirus (HPeV) are 2 viruses belonging to the same family of Picornaviridae. The clinical manifestations of HPeV infection are often indistinguishable from those caused by EV. Infections with these viruses are prevalent in children and generally cause mild upper respiratory and gastrointestinal illnesses. 1 Over the past decades, large outbreaks of EV/HPeV have been documented worldwide. 2 During these outbreaks, an increase in more severe illnesses, including sepsis-like illness, myocarditis, pneumonia, myelitis and meningoencephalitis, has been reported. [3] [4] [5] Unfortunately, there are no antivirals approved of the treatment of EV/HPeV, and management remains mainly supportive.
In England and Wales, where the last EV/HPeV outbreak was caused by echovirus 13 during 2000-2001, we recently identified a year-on-year increase in reports of laboratoryconfirmed EV cases across all age groups, most likely because of increasing use of routine polymerase chain reaction (PCR) testing by hospital laboratories. 6 At the same time, we also identified rare but severe cases of childhood EV/HPeV through our national surveillance of EV/HPeV meningoencephalitis in young infants (http://www.rcpch.ac.uk/bpsu/neoentero), retrospective case-note review 7 and individual cases. 8 To better define the burden of severe childhood EV/HPeV infections, we analyzed data for all pediatric intensive care admissions in the United Kingdom and the Republic of Ireland during the 5 most recent calendar years.
methods
The Paediatric Intensive Care Audit Network (PICANet) records core demographic and clinical details of the management of all critically ill children in pediatric intensive care units (PICUs) across the United Kingdom and the Republic of Ireland, using standardized data collection forms (www.picanet.org).
We requested anonymized data on all children of 0-15 years of age, admitted to PICU in the United Kingdom and the Republic of Ireland between January 1, 2010, and December 31, 2014, with any one of the following recorded at any time during their admission: "EV," "echovirus," "HPeV," "picornavirus," "coxsackievirus" or "enteroviral." The final data set had information on the month and year of admission, age (in days for neonates, in months for infants and in years for older children), gender, outcome (alive/dead), primary, secondary and subsequent diagnoses (codes and description), The male-to-female ratio was 1.6:1. Analysis of cases by month of year revealed a bimodal distribution, with peaks in June-July and October-November. The majority of cases were younger than 1 year (86/104, 83%), 9 (9%) were 1 year old and 9 (9%) were 2 (n = 5) years or older (n = 4). Neurologic presentations were most common (42/104, 40%), followed by respiratory (n = 21, 20%), cardiac (n = 17, 16%) and sepsis-like illness (n = 11, 11%). The remaining 13 children (13%) had nonspecific clinical presentations (fever, collapse, etc.) ( Table 1) . Neurologic presentations were more common in infants younger than 3 months (34/74, 46%) compared with older children (8/30, 27%), but the difference was not significant (P = 0.069) (Fig. 1) .
The majority of children required invasive ventilation (80/104, 77%; median: 5 days, range: 1-49 days) and 40% (42/104) required inotropic support (median: 5 days; range: 1-48 days), while 4/98 children with available information (4%) needed renal hemofiltration (median: 3 days; range: 1-8 days) and 3 (3%) were severe enough to require ECMO (median: 8 days; range: 2-12 days). Eight children (8%) died during their stay in PICU, including 2 (1 cardiac presentation, 1 respiratory presentation) who had severe underlying neurodevelopmental comorbidities. Although there were only a few such cases, children with cardiac manifestations appeared to require more intensive care support and also more likely to die in PICU (Table 1) .
dIsCussIon
We have attempted to define the burden of severe childhood EV/HPeV infections in the United Kingdom and the Republic of Ireland during a stable period when no outbreaks are known to have occurred. Over the 5 years of observation, there was a 3-fold increase in EV/HPeV-associated PICU admissions, consistent with national trends, most likely because of increasing use of PCR testing for these viruses in local hospitals. 6 In 2014, EV/HPeV infections were associated with 1.8 per 1000 PICU admissions, but this is likely to be a significant underestimate because it requires the diagnosis to be made while the child is still an inpatient in the PICU. PCR testing for EV/HPeV is usually only performed in large hospitals and there, too, such tests are often not performed on a daily basis. Hence, in a significant proportion of cases, the diagnosis would only be confirmed after PICU discharge. It is likely that case ascertainment will continue to increase as PCR testing becomes more widely available and incorporated into routine clinical practice.
Our series of cases is unique in that it captures all clinical presentations to PICU caused by all different EV/HPeV types in a national setting in a 5-year period. Moreover, unlike much of the published literature, the cases were identified when there was no outbreak and therefore no particular EV/HPeV type dominated. Our findings indicate that young infants account for the majority 5-year period, from 0.6/1000 pediatric intensive care unit admissions (12 cases) in 2010 to 1.8/1000 (36 cases) in 2014. Most cases (n = 86, 83%) were younger than 1 year; 77% (n = 80) required invasive ventilation, 40% (n = 42) inotropic support, 4% (n = 4) renal dialysis and 3% (n = 3) extracorporeal membrane oxygenation. Eight children (8%) died, including 4 with cardiac complications.
of children with EV/HPeV infections who require PICU admission. Most were extremely ill, often requiring multiorgan support. In particular, although there were only 17 children with cardiac presentations, nearly all required inotropic support. Moreover, 2 of the 4 children requiring dialysis, 2 of the 3 children requiring ECMO support and half the fatalities occurred in this group.
Rare but severe cases of EV/HPeV myocarditis are well reported. In a recent case series from London, United Kingdom, 5 young infants with acute fulminant myocarditis presented to their local hospital with nonspecific symptoms such as vomiting, cough and poor feeding, but rapid deterioration prompted referral for intensive care. 9 Two children died before transfer, while 1 of the 3 survivors needed urgent orthotopic heart transplantation. The authors recommended that myocarditis should be considered in any previously well child presenting with a viral prodrome and nonspecific organ dysfunction associated with dysrhythmias, shock or acute heart failure, even without cardiomegaly. In another study, only 8/24 (33%) with enteroviral myocarditis requiring ECMO survived. 10 Multiple organ dysfunction, particularly with renal involvement, may portend a poor prognosis, highlighting the importance of rapid diagnosis to ensure early and appropriate supportive care.
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A limitation of our study is that PICANet does not collect extensive data on presenting symptoms or interventions other than those specified in our report. Another limitation of our study is that diagnosis may not be confirmed until after the children are discharged from PICU and that may substantially underestimate the true burden of EV/HPeV infections in children admitted to PICU. A cute sore throat is one of the most common indications for children to be evaluated in the primary care or urgent care setting. Group A streptococcus (GAS) is responsible for 15%-30% of cases of acute pharyngitis in children. 1 Despite the fact that GAS are universally susceptible to penicillin, the use of macrolides, especially azithromycin (because of convenience of dosing and duration of treatment regimens), has become popular for treating GAS pharyngitis and other respiratory infections. Resistance to macrolides among GAS has been known for over 40 years both within and outside of the United States. 2, 3 We report macrolide resistance rates in a primary care setting in our geographic area over the past 5 years and discuss the implications of resistance in making treatment decisions regarding antimicrobials.
methods
A convenience sample of children was recruited from 1 of 2 pediatric primary care practice-based clinics in Madison, Wisconsin, from May 2011 to May 2015 as a part of the study on the pathogenesis of GAS infections in children. Children with sore throat were eligible to participate if they were 4-15 years of age, had not been treated with antibiotics in the past 30 days and had a positive rapid antigen detection test (RADT) for GAS. Because this was part of a larger protocol that involved treatment, patients were excluded if they had a significant allergy to a beta-lactam antibiotics. Samples from the posterior pharynx and the tonsillar pillars were collected with a double swab at the time of presentation. One swab was used for the RADT and the second swab was sent for bacterial culture and antimicrobial susceptibility testing. All children were treated with an appropriate antimicrobial at the discretion of the attending physician.
Throat swabs were placed in Todd-Hewitt broth (Teknova, Hollister, CA), vortexed and incubated overnight at 37°C. The swab was then inoculated onto SXT blood agar plates. Beta-hemolytic colonies were confirmed as GAS by gram staining, pyrrolidonyl arylamidase test and latex agglutination test (PathoDx; Remel, Remel Lenexa, KS).
Susceptibility testing was performed for erythromycin and clindamycin (BBL Sensi-disc, BD, Becton, Dickinson Franklin Lakes, NJ) using the Kirby-Bauer disk diffusion method. A 0.5 McFarland suspension of the bacteria was inoculated as a lawn onto Mueller Hinton agar supplemented with 5% sheep blood (Remel). Antibiotic disks were added and plates were incubated overnight at 37°C and 10% CO 2 . Clinical Laboratory and Standards Institute standards were used as breakpoints for resistant, intermediate and susceptible. The D-test was used to detect erythromycin-induced resistance to clindamycin.
The Cochran-Armitage Trend test was used to evaluate whether there is a change in the rate of nonsusceptibility over the 5 years of the study.
results
A total of 155 children with pharyngitis were enrolled in the study. Twelve children were excluded when GAS were not identified on culture from the second swab, leaving a total of 143 isolates that were available for analysis. Demographic information was available for 139 children. The mean age was 9.2 years, and there was a preponderance of male patients (58% 
